Gérard Flesch

1.7k total citations
30 papers, 1.3k citations indexed

About

Gérard Flesch is a scholar working on Pediatrics, Perinatology and Child Health, Oncology and Psychiatry and Mental health. According to data from OpenAlex, Gérard Flesch has authored 30 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pediatrics, Perinatology and Child Health, 11 papers in Oncology and 8 papers in Psychiatry and Mental health. Recurrent topics in Gérard Flesch's work include Epilepsy research and treatment (8 papers), Pharmacological Effects and Toxicity Studies (8 papers) and Drug Transport and Resistance Mechanisms (6 papers). Gérard Flesch is often cited by papers focused on Epilepsy research and treatment (8 papers), Pharmacological Effects and Toxicity Studies (8 papers) and Drug Transport and Resistance Mechanisms (6 papers). Gérard Flesch collaborates with scholars based in Switzerland, United States and Denmark. Gérard Flesch's co-authors include Peter Lloyd, Philipp Müller, W. Dieterle, Suzanne Hauffe, P.H. Degen, Marc de Gasparo, Felix Waldmeier, J. D’Souza, Edwin Walker and Christian E. Elger and has published in prestigious journals such as Blood, JNCI Journal of the National Cancer Institute and Journal of Bone and Mineral Research.

In The Last Decade

Gérard Flesch

29 papers receiving 1.3k citations

Peers

Countries citing papers authored by Gérard Flesch

Since Specialization

Citations

This map shows the geographic impact of Gérard Flesch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gérard Flesch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gérard Flesch more than expected).

Fields of papers citing papers by Gérard Flesch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gérard Flesch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gérard Flesch. The network helps show where Gérard Flesch may publish in the future.

Co-authorship network of co-authors of Gérard Flesch

This figure shows the co-authorship network connecting the top 25 collaborators of Gérard Flesch. A scholar is included among the top collaborators of Gérard Flesch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gérard Flesch. Gérard Flesch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pharmacokinetics of the Monohydroxy Derivative of Oxcarbazepine and Its Enantiomers after a Single Intravenous Dose Given as Racemate Compared with a Single Oral Dose of Oxcarbazepine 2011 ·Drug Metabolism and Disposition ·Gérard Flesch, (unknown), Didier Renard, Peter Lloyd	35
2	Overview of the Clinical Pharmacokinetics of Oxcarbazepine 2004 ·Clinical Drug Investigation ·Gérard Flesch	86
3	Assessment of the bioequivalence of two oxcarbazepine oral suspensions versus a film-coated tablet in healthy subjects 2003 ·International Journal of Clinical Pharmacology and Therapeutics ·Gérard Flesch, (unknown), J. Denouël, (unknown), R. Camisasca	13
4	Oxcarbazepine final market image tablet formulation bioequivalence study after single administration and at steady state in healthy subjects 2002 ·International Journal of Clinical Pharmacology and Therapeutics ·Gérard Flesch, (unknown), C. Souppart, J. D’Souza, Mohammad Sharif Hossain	9
5	Intravenous Pamidronate for Treatment of Reflex Sympathetic Dystrophy During Breast Feeding 2000 ·Journal of Bone and Mineral Research ·Kerry Siminoski, Avril A. Fitzgerald, Gérard Flesch, (unknown)	26
6	An interaction study with cimetidine and the new angiotensin II antagonist valsartan 1998 ·European Journal of Clinical Pharmacology ·Erika Schmidt, K. H. Antonin, Gérard Flesch, Amy Racine-Poon	34
7	Pharmacokinetics of valsartan in patients with liver disease 1997 ·Clinical Pharmacology & Therapeutics ·L Brookman, Paul Rolan, I S Benjamin, K Palmér, P.J. Wyld, Peter Lloyd, Gérard Flesch, Felix Waldmeier, A. Sioufi, (unknown)	77
8	Quantitative determination of CGP 61755, a protease inhibitor, in plasma and urine by high-performance liquid chromatography and fluorescence detection 1997 ·Journal of Chromatography B Biomedical Sciences and Applications ·Gérard Flesch, (unknown), P.H. Degen	4
9	Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man 1997 ·European Journal of Clinical Pharmacology ·Gérard Flesch, Philipp Müller, Peter Lloyd	173
10	Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose 1997 ·Xenobiotica ·Felix Waldmeier, Gérard Flesch, (unknown), T. WINKLER, H.‐P. KRIEMLER, Peter Bühlmayer, Marc de Gasparo	118
11	Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide 1997 ·European Journal of Clinical Pharmacology ·(unknown), P.H. Degen, Gérard Flesch, Marc de Gasparo, (unknown)	24
12	Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state 1995 ·Biopharmaceutics & Drug Disposition ·J Cardot, P.H. Degen, Gérard Flesch, (unknown), W. Dieterle	21
13	The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers 1994 ·Biopharmaceutics & Drug Disposition ·P.H. Degen, Gérard Flesch, J Cardot, (unknown), W. Dieterle	23
14	Quantitative determination of CGP 53 437, a new HIV protease inhibitor, in plasma by high-performance liquid chromatography and fluorescence detection 1994 ·Journal of Chromatography B Biomedical Sciences and Applications ·Gérard Flesch, (unknown), (unknown), (unknown), P.H. Degen, W. Dieterle	2
15	Clinical Pharmacology and Pharmacokinetics of Oxcarbazepine 1994 ·Epilepsia ·Peter Lloyd, Gérard Flesch, W. Dieterle	121
16	Urinary Excretion of Aminohydroxypropylidene Bisphosphonate in Cancer Patients after Single Intravenous Infusions 1993 ·Journal of Pharmaceutical Sciences ·(unknown), (unknown), Keith K. H. Chan, John J. Seaman, P.H. Degen, Gérard Flesch, Alan Brox, (unknown)	8
17	Pharmacokinetic evaluation of pamidronate after oral administration: A study on dose proportionality, absolute bioavailability, and effect of repeated administration 1993 ·Calcified Tissue International ·Lars Hyldstrup, Gérard Flesch, Suzanne Hauffe	39
18	Influence of infusion rate on the pharmacokinetics of intravenous pamidronate (apd) in patients with bone metastases 1993 ·(unknown), Gérard Flesch, Serge Leyvraz, U Hess, Suzanne Hauffe	1
19	Determination of the R-(−) and S-(+) enantiomers of the monohydroxylated metabolite of oxcarbazepine in human plasma by enantioselective high-performance liquid chromatography 1992 ·Journal of Chromatography B Biomedical Sciences and Applications ·Gérard Flesch, Eric Francotte, (unknown), P.H. Degen	40
20	Pharmacokinetics of Pamidronate in Patients With Bone Metastases 1992 ·JNCI Journal of the National Cancer Institute ·Serge Leyvraz, U Hess, Gérard Flesch, Jean Bauer, Suzanne Hauffe, J. Ford, P. Burckhardt	60

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact